Research programme: anticancer antibodies - MMRGlobal

Drug Profile

Research programme: anticancer antibodies - MMRGlobal

Alternative Names: Anti-CD20 monoclonal antibodies - MMR Information Systems; Anti-CD20 monoclonal antibodies -MMRGlobal

Latest Information Update: 07 Feb 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Diversa
  • Developer MMRGlobal
  • Class Monoclonal antibodies
  • Mechanism of Action CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Non-Hodgkin's lymphoma

Most Recent Events

  • 03 Feb 2015 MMRGlobal has patent protection for methods of treatment using the anti-CD20 monoclonal antibodies in USA
  • 30 Nov 2011 Research programme: anticancer antibodies - MMR Information Systems is available for licensing as of 30 Nov 2011.
  • 15 Jun 2010 MMR Information Systems is now called MMRGlobal
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top